Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r
MMW Fortschritte der Medizin 145(50): 61
2003
ISSN/ISBN: 1438-3276 PMID: 14963981 Document Number: 559710
Document emailed within 1 workday
Related Documents
Barthélémy, O.; Escaut, L.; Vayre, F.; Gallet, B.; Pulik, M.; Heloire, F.; Vittecoq, D. 2002: Acute coronary syndromes in patients treated with HIV protease inhibitors Presse Medicale 31(8): 343-348Colombo, S.; Buclin, T.; Franc, C.; Guignard, N.; Khonkarly, M.; Tarr, P.E.; Rochat, B.; Biollaz, J.ér.ôm.; Telenti, A.; Decosterd, L.A.; Cavassini, M. 2006: Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures Antiviral Therapy 11(1): 53-62
Ananworanich, J.; Hirschel, B.; Sirivichayakul, S.; Ubolyam, S.; Jupimai, T.; Prasithsirikul, W.; Chetchotisakd, P.; Kiertiburanakul, S.; Munsakul, W.; Raksakulkarn, P.; Tansuphasawadikul, S.; Schutz, M.; Snowden, W.; Ruxrungtham, K. 2006: Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir Antiviral Therapy 11(5): 631-635
Locutura, J.; Lorenzo, J.F.; Miján, A. 1999: Portal thrombosis in a female patient treated with protease inhibitors Medicina Clinica 112(9): 359
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Kovacić, Z.; Ivanisević, M.; Stanić, R.; Bojić, L.; Capkun, V.; Rogosića, V. 2007: Additive therapy with carboanhydrase inhibitors for open angle glaucoma previously treated with timolol 0.5% drops Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 61(4): 417-419
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Choi, J.-y.; Kwon, O.-K.; Choi, S.Y.; Park, Y.K.; Kim, S.S. 2011: Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 50(1): 19-25
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Mullakandov, S.A.; Gafarov, E.K.; Nabiev, U.A. 1985: Use of protease inhibitors on burn patients Klinicheskaia Khirurgiia 3: 43-44
Sommadossi; Murphy 1997: Protease Inhibitors Therapy for AIDS Patients Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases 1(5): 226-229
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Piatkowska, M.; Kotschy, M.; Rość, D.; Wiśniewska, E.; Opoka, J. 1994: Plasma serine protease inhibitors in patients with liver cirrhosis Acta Haematologica Polonica 25(2): 145-149
Swiatkowski, M.; Pulkowski, G.; Kłopocka, M.; Budzyński, J.; Wiśniewsk, E.; Kotschy, M. 2001: Serine protease inhibitors in plasma of patients with ulcerative colitis Przeglad Lekarski 58(2): 67-70
Chronister, C.L.; Gurwood, A.S. 1998: Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients Journal of the American Optometric Association 69(11): 695-698
Kłoczko, J.; Bielawiec, M.; Galar, M.; Czaczkowska, T.; Wojtukiewicz, M. 1991: Protein C and plasma serine protease inhibitors in patients with essential hypertension Polski Tygodnik Lekarski 46(50-52): 974-976
Gurgo, A.M.; Massino Ferri, F.; Iulianella, R.; Luciani, C.; Lucifero, A.; Staropoli, P.; Rocchi, M. 2001: Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 2(11): 1236-1239
Sumathi, S.; Pattabiraman, T.N. 1976: Natural plant enzyme inhibitors: Part II-protease inhibitors of seeds Indian Journal of Biochemistry and Biophysics 13(1): 52-56
Bhat, P.G.; Karnik, S.S.; Pattabiraman, T.N. 1976: Natural plant enzyme inhibitors: Part III-purification of protease inhibitors from Lathyrus sativus seeds Indian Journal of Biochemistry and Biophysics 13(4): 339-343